AHFS March 2024 Update

This update contains 5 new monographs, 28 revised monographs, 10 discontinued monographs and 2 new MedWatch alerts.

New monographs: Chikungunya Vaccine Live; Eplontersen Sodium; Exagamglogene Autotemcel; Lovotibeglogene autotemcel; Sotagliflozin.

Revised monographs: Aducanumab; Atogepant; Belumosudil Mesylate; Crizotinib; Deferasirox; Denosumab; Difelikefalin Acetate; Elacestrant Hydrochloride; Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate; Emapalumab; Etravirine; Filgrastim; Fostamatinib Disodium Hexahydrate; inFLIXimab; Lecanemab; Maralixibat Chloride; Mavacamten; Nivolumab and Relatlimab; Norepinephrine Bitartate; Raltegravir Potassium; Ravulizumab; Relugolix, Estradiol, and Norethindrone Acetate; Retifanlimab; Setmelanotide Acetate; Sirolimus (Immunosuppressive Agent); Temsirolimus; Trofinetide; Vonoprazan.

Discontinued monographs: Abciximab; Anti-infectives Available from CDC; COVID-19 Vaccine (Janssen); Eflornithine; HYDROXYprogesterone; Immunization Schedules; Immunobiologic Agents Available from CDC; Measles, Mumps, and Rubella Vaccine; Mobocertinib; Vonoprazan, Clarithromycin, and Amoxicillin.

New MedWatch alerts on the following monographs: Semaglutide; Sotagliflozin.